News | Thrombectomy Devices | February 05, 2019

Delayed Clot Removal Still Improves Quality of Life Post-Stroke

Patients surveyed in DEFUSE 3 trial had better quality of life with thrombectomy up to 24 hours after symptom onset compared to medical therapy alone

Delayed Clot Removal Still Improves Quality of Life Post-Stroke

February 5, 2019  — Stroke survivors have better quality of life three months after their stroke if the clot that caused the stroke was mechanically removed even hours beyond the ideal treatment window compared to those treated with drugs alone. This preliminary research will be presented, Feb. 6-8 in Honolulu at the American Stroke Association’s International Stroke Conference 2019.

Researchers have found that mechanically removing a clot in stroke patients, called endovascular therapy, can limit disability from stroke. While the therapy is most effective when performed within six hours of symptom onset, it can also reduce functional deficits in patients up to 24 hours after stroke symptoms start.

In the DEFUSE 3 trial, Stanford University School of Medicine researchers studied whether stroke survivors who were treated with endovascular therapy in the late six-to-16-hour time window might have better quality of life than people treated only with standard drug therapy. They examined a subset of ischemic stroke patients who had salvageable tissue visible on brain imaging.

Researchers surveyed patients 90 days after stroke about their mobility, ability to participate in social activities, cognitive (or thinking) function and depression.

Based on results from 136 patients who completed all or some of the surveys, people treated with endovascular therapy had superior quality-of-life results in all four domains, compared to those who had medical therapy alone.

“In addition to improved functional outcomes, endovascular therapy six to 16 hours after onset preserves mental health and social capabilities critical to patients’ quality of life,” researchers said.

For more information: www.professional.heart.org


Related Content

News | Thrombectomy Devices

June 16, 2025 – Penumbra, Inc. recently announced the completion of enrollment in the STORM-PE clinical trial. This ...

Home June 16, 2025
Home
News | Thrombectomy Devices

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ...

Home March 24, 2025
Home
News | Thrombectomy Devices

Penumbra recently launched its Element Vascular Access System, a laser-cut hypotube sheath designed for venous ...

Home January 30, 2025
Home
News | Thrombectomy Devices

Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary ...

Home November 07, 2024
Home
News | Thrombectomy Devices

Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Food and Drug Administration (FDA) has ...

Home September 24, 2024
Home
News | Thrombectomy Devices

Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the ...

Home September 10, 2024
Home
News | Thrombectomy Devices

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
Feature | Thrombectomy Devices | By Global Market Insights

The global thrombectomy devices market is poised to experience substantial expansion, owing to the emergence of ...

Home June 27, 2022
Home
News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
News | Thrombectomy Devices

November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter ...

Home November 12, 2021
Home
Subscribe Now